vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and RBC Bearings INC (RBC). Click either name above to swap in a different company.
RBC Bearings INC is the larger business by last-quarter revenue ($461.6M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). RBC Bearings INC runs the higher net margin — 14.6% vs 11.1%, a 3.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 17.0%). RBC Bearings INC produced more free cash flow last quarter ($99.1M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Dover Corporation is an American conglomerate manufacturer of industrial products. The Downers Grove, Illinois-based company was founded in 1955. As of 2021, Dover's business was divided into five segments: Engineered Products, Clean Energy and Fueling, Imaging & Identification, Pumps & Process Solutions and Climate and Sustainability Technologies. Dover is a constituent of the S&P 500 index and trades on the New York Stock Exchange under the symbol DOV. Dover was ranked 448 in the 2024 Fortu...
ANIP vs RBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $461.6M |
| Net Profit | $27.5M | $67.4M |
| Gross Margin | — | 44.3% |
| Operating Margin | 14.1% | 22.3% |
| Net Margin | 11.1% | 14.6% |
| Revenue YoY | 29.6% | 17.0% |
| Net Profit YoY | 367.5% | 16.4% |
| EPS (diluted) | $1.14 | $2.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $461.6M | ||
| Q3 25 | $227.8M | $455.3M | ||
| Q2 25 | $211.4M | $436.0M | ||
| Q1 25 | $197.1M | $437.7M | ||
| Q4 24 | $190.6M | $394.4M | ||
| Q3 24 | $148.3M | $397.9M | ||
| Q2 24 | $138.0M | $406.3M | ||
| Q1 24 | $137.4M | $413.7M |
| Q4 25 | $27.5M | $67.4M | ||
| Q3 25 | $26.6M | $60.0M | ||
| Q2 25 | $8.5M | $68.5M | ||
| Q1 25 | $15.7M | $72.7M | ||
| Q4 24 | $-10.3M | $57.9M | ||
| Q3 24 | $-24.2M | $54.2M | ||
| Q2 24 | $-2.3M | $61.4M | ||
| Q1 24 | $18.2M | — |
| Q4 25 | — | 44.3% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | — | 44.8% | ||
| Q1 25 | — | 44.2% | ||
| Q4 24 | — | 44.3% | ||
| Q3 24 | — | 43.7% | ||
| Q2 24 | — | 45.3% | ||
| Q1 24 | — | 43.1% |
| Q4 25 | 14.1% | 22.3% | ||
| Q3 25 | 15.9% | 21.5% | ||
| Q2 25 | 6.6% | 23.2% | ||
| Q1 25 | 13.3% | 23.0% | ||
| Q4 24 | -2.3% | 21.7% | ||
| Q3 24 | -13.8% | 21.6% | ||
| Q2 24 | 3.7% | 24.0% | ||
| Q1 24 | 14.8% | 22.8% |
| Q4 25 | 11.1% | 14.6% | ||
| Q3 25 | 11.7% | 13.2% | ||
| Q2 25 | 4.0% | 15.7% | ||
| Q1 25 | 8.0% | 16.6% | ||
| Q4 24 | -5.4% | 14.7% | ||
| Q3 24 | -16.3% | 13.6% | ||
| Q2 24 | -1.7% | 15.1% | ||
| Q1 24 | 13.2% | — |
| Q4 25 | $1.14 | $2.13 | ||
| Q3 25 | $1.13 | $1.90 | ||
| Q2 25 | $0.36 | $2.17 | ||
| Q1 25 | $0.69 | $2.33 | ||
| Q4 24 | $-0.45 | $1.82 | ||
| Q3 24 | $-1.27 | $1.65 | ||
| Q2 24 | $-0.14 | $1.90 | ||
| Q1 24 | $0.82 | $1.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $107.6M |
| Total DebtLower is stronger | — | $990.2M |
| Stockholders' EquityBook value | $540.7M | $3.3B |
| Total Assets | $1.4B | $5.1B |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $107.6M | ||
| Q3 25 | $262.6M | $91.2M | ||
| Q2 25 | $217.8M | $132.9M | ||
| Q1 25 | $149.8M | $36.8M | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | $76.8M | ||
| Q1 24 | $228.6M | $63.5M |
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $540.7M | $3.3B | ||
| Q3 25 | $505.8M | $3.2B | ||
| Q2 25 | $436.8M | $3.1B | ||
| Q1 25 | $418.6M | $3.0B | ||
| Q4 24 | $403.7M | $2.9B | ||
| Q3 24 | $405.9M | $2.9B | ||
| Q2 24 | $455.8M | $2.8B | ||
| Q1 24 | $452.0M | $2.8B |
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.3B | $4.8B | ||
| Q1 25 | $1.3B | $4.7B | ||
| Q4 24 | $1.3B | $4.7B | ||
| Q3 24 | $1.3B | $4.7B | ||
| Q2 24 | $920.8M | $4.7B | ||
| Q1 24 | $914.5M | $4.7B |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $122.1M |
| Free Cash FlowOCF − Capex | $29.1M | $99.1M |
| FCF MarginFCF / Revenue | 11.8% | 21.5% |
| Capex IntensityCapex / Revenue | 0.5% | 5.0% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $122.1M | ||
| Q3 25 | $44.1M | $88.4M | ||
| Q2 25 | $75.8M | $120.0M | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $15.9M | $84.0M | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $17.4M | $97.4M | ||
| Q1 24 | $18.3M | — |
| Q4 25 | $29.1M | $99.1M | ||
| Q3 25 | $38.0M | $71.7M | ||
| Q2 25 | $71.8M | $104.3M | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | $73.6M | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | $88.4M | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | 21.5% | ||
| Q3 25 | 16.7% | 15.7% | ||
| Q2 25 | 34.0% | 23.9% | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | 18.7% | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | 21.8% | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | 5.0% | ||
| Q3 25 | 2.7% | 3.7% | ||
| Q2 25 | 1.9% | 3.6% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 1.3% | 2.6% | ||
| Q3 24 | 3.2% | 4.1% | ||
| Q2 24 | 3.2% | 2.2% | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 1.81× | ||
| Q3 25 | 1.66× | 1.47× | ||
| Q2 25 | 8.87× | 1.75× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.59× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
